Asthma
Severe asthma
resolves to
Th2-high, IL-5-driven eosinophilic asthma
- Confidence
- 92%
- Treatment
- Mepolizumab or benralizumab
- Why it matters
- 78% predicted response
Molecular resolution for precision medicine
From phenotype to endotype.
EndoPheno reads downward. It matches a patient's genetic and biomarker signature against a curated database of polygenic scores and endotype literature, then resolves a broad diagnosis into the specific biological pathway driving it, and the therapy that targets it. Every call carries a citation trail.
The four-layer model
Where medicine starts today. Clinical lumping by appearance, the label a 15-minute visit produces.
Observable traits and basic labs. Sharper, but still observer-dependent.
The destination. The specific biological pathway driving the phenotype. Stable, mechanistic, treatment-determining.
The payoff. Endotype mapped to a specific therapy with a response probability.
The EndoPheno equation
Genotype × Exposome → Phenotype
Phenotype + Molecular Resolution → Endotype
EndoPheno is the molecular resolution layer.
The processing engine
Patient signature in
Molecular resolution
Fueled by a proprietary knowledge graph: 100k+ articles, 4,700+ scores, PRS-PGx data.
Patient output
Three anchor examples
Asthma
resolves to
Breast cancer
resolves to
Cardiometabolic
resolves to
Clinicians already order overall polygenic risk scores. EndoPheno is the subtype layer they currently lack.
Request access
Tell us who you are and we'll be in touch. We review every request by hand.